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Abstract
Background: The incidence of thyroid cancer has progressively increased over the past few decades, and the most
frequent types of this cancer are papillary thyroid carcinoma (PTC) and small primary tumors. In PTC, oncogene
activation is known to occur at a high frequency. However, the potential roles of tumor suppressor genes in thyroid
carcinogenesis remain unclear. LDOC1 was first identified as a gene encoding a leucine zipper protein whose
expression was decreased in a series of pancreatic and gastric cancer cell lines. In this study, we aimed to
determine the status of LDOC1 in PTC and identify its mechanistic role in PTC pathogenesis.
Methods: LDOC1 expression was evaluated in fresh samples and stored specimens of human PTC and contralateral
normal tissues by performing quantitative reverse transcription-PCR and immunohistochemical staining. The
correlation to nuclear p65 content in the stored specimens was analyzed. Moreover, the basal level of LDOC1 in
two human PTC-derived cell lines (BCPAP and TPC-1) compared with normal thyroid tissue was determined.
Human LDOC1 cDNA was inserted into a lentiviral vector and transduced into TPC-1 cells. TPC-1 cells
overexpressing LDOC1/GFP (Lv-LDOC1) or negative control GFP (Lv-NC) were stimulated with TNFα or recombinant
TGF-β1, and then cell proliferation, cell cycle distribution, and apoptosis were assessed. Western blotting was used
to examine the expression of p65, IκBα, c-Myc, Bax, and Bcl-xL, and a luciferase reporter assay was used to measure
NF-κB activity stimulated by TNFα. Statistical significance was determined using Student’s t tests or ANOVA and
Newman-Keuls multiple comparison tests. Pearson chi-square test was used to analyze possible associations.
Results: LDOC1 expression was significantly downregulated in PTC specimens as compared with the expression in
normal thyroid tissues, and this downregulation was associated with an increase in tumor size (P < 0.05). There is a
correlation between LDOC1 and nuclear P65 expression in human PTC tissues (P < 0.01). Lentivirus-mediated
restoration of LDOC1 expression in TPC-1 cells characterized by low level of LDOC1 expression suppressed
proliferation and induced apoptosis by inhibiting NF-κB activation, and LDOC1-overexpressing TPC-1 cells recovered
responsiveness to TGF-β1 antiproliferative signaling.
Conclusions: LDOC1 might function as a tumor suppressor gene in PTC by inhibiting NF-κΒ signaling, and thus
might represent a promising therapeutic target in patients with PTC.
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Background
Thyroid cancer is currently the most common endocrine
malignancy, and its incidence accounts for >5 % of all
cancers in women [1]. Papillary thyroid carcinoma
(PTC), the most prevalent histotype among thyroid
malignancies [2], is typically well-differentiated and asso-
ciated with a favorable therapeutic response and progno-
sis; however, in the case of aggressive PTC and certain
PTC variants, around 10 % of the patients manifest re-
currences or distant metastases within 10 years [3–5].
Thus, although the roles of several specific genes in PTC
have been established, other biomarkers are required to
improve patient stratification for the purpose of deter-
mining the most effective therapeutic options and
follow-up strategies and identifying novel therapeutic
targets for PTC.
Various oncogenes have been identified to be involved
in human thyroid cancers, particularly in the papillary
histotype [6, 7]. Mutations in the gene BRAF represent
the predominant molecular alterations in PTCs [8, 9],
and activation of the RET/PTC oncogene [10] has been
identified in approximately 20 % of PTCs. In tumor pro-
gression in general, the early stages are characterized by
both the silencing of tumor suppressor genes [11, 12]
and an enhanced expression of oncogenes [13–15]. In
the case of PTC in particular, oncogene activation is
known to occur at a high frequency, but the tumor sup-
pressor genes involved remain poorly elucidated.
Leucine zipper downregulated in cancer 1 (LDOC1)
was originally identified using differential RNA display
to be downregulated in a series of pancreatic and gastric
cancer cell lines [16]. The LDOC1 protein contains a
DNA-binding leucine zipper-like motif and a short
proline-rich region. LDOC1 downregulation and differ-
ential expression have also been characterized in tissue
samples of esophageal cancer [17] and various types of
leukemia [18], which suggests that LDOC1 likely func-
tions as a tumor suppressor. Furthermore, LDOC1 has
been described to regulate NF-κB activation in human
cancer cells [19, 20] and biliary epithelial cells [21]. The
NF-κB signaling pathway is widely recognized to play a
major role in the initiation and progression of thyroid
carcinoma [22–26]. However, the expression and func-
tion of LDOC1 in PTC remain unclear.
In this study, we validated the downregulation of
LDOC1 in human PTC tissue samples and its relation-
ship to tumor size and nuclear p65 content. We further
show that LDOC1 can suppress PTC cell growth and in-
duce apoptosis. Notably, LDOC1 sensitizes PTC cells to
apoptosis by regulating NF-κB activation, and, conse-
quently, modulates the responsiveness of these cells to
TGF-β1 antiproliferative signaling. These data suggest
that LDOC1 functions as a putative tumor suppressor
gene in thyroid tumorigenesis.
Methods
Thyroid tissue specimens
Human thyroid tissue samples were collected at The First
Affiliated Hospital of Zhengzhou University between 2013
and 2014. Fresh PTC tissue specimens (n = 126) and con-
trol samples (contralateral normal thyroid lobe, n = 47)
were frozen in liquid nitrogen immediately after thy-
roidectomy and stored at −80 °C. These samples were
analyzed using quantitative reverse transcription-PCR
(qRT-PCR). Stored, formalin-fixed, paraffin-embedded
cancer tissues obtained from 56 patients with PTC
were investigated using immunohistochemical stain-
ing, with 33 contralateral normal thyroid specimens
serving as control samples. All tissue samples used in
this study were diagnosed by two endocrine patholo-
gists, and representative tumor areas were selected
for analysis.
This study was conducted in accordance with the
Helsinki Declaration and was approved by the Ethics
Committee of The First Affiliated Hospital of Zhengzhou
University. All participants provided written informed
consent for the use of the samples in the study.
Thyroid cell line and cell culture
The PTC-derived thyroid cell line TPC-1 was kindly
provided by Professor Li-li Zheng (The First Affiliated
Hospital of Zhengzhou University, Zhengzhou, China).
Cell line BCPAP was obtained from Chinese Academy of
Sciences (Shanghai, China). Cells were cultivated in
DMEM supplemented with 10 % fetal calf serum in a
5 % CO2 atmosphere at 37 °C.
Lentivirus-mediated LDOC1 overexpression in TPC-1 cells
Human LDOC1 cDNA was amplified, purified, and
inserted into a lentiviral vector encoding enhanced GFP
[27, 28]. The recombinant lentiviral vector expressing
LDOC1 (Lv-LDOC1) and the empty vector (Lv-NC;
negative control, encoding GFP alone) were constructed
by Shanghai GenePharma Co., Ltd. (Shanghai, China)
and verified by sequencing. Packaging, purification, and
titer determination of the recombinant lentiviruses were
implemented in HEK293T cells as previously described
[29, 30]. In two precise preparations, the titers of the re-
combinant lentiviruses were 2 × 108 and 5 × 108 infec-
tious units/mL, respectively.
TPC-1 cells were cultured in 24-well plates and in-
fected with the lentivirus at a multiplicity of infection
(MOI) of 20, 50, or 100 for 24 h. Flow cytometry analysis
revealed that approximately 95 % of the cells were infected
at an MOI of 50. To obtain stable LDOC1 expression,
cells were selected using puromycin (Sigma-Aldrich, St.
Louis, MO, USA), and LDOC1 expression in the infected
cells was validated by means of qRT-PCR and western
blotting.
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RNA isolation and qRT-PCR
Total RNA was extracted from frozen samples of hu-
man tissue and from cells by using TRIzol reagent
(Invitrogen, San Francisco, CA, USA) according to
the manufacturer’s instructions. RNA integrity was
assessed by performing denaturing agarose-gel elec-
trophoresis, and then 1 μg of total RNA was used for
first-strand cDNA synthesis by using the Superscript
III First-Strand Synthesis system (Toyobo, Osaka,
Shiga, Japan); the volume of each reaction was 10 μL,
and cDNA synthesis was performed under these ther-
mal conditions: 37 °C for 15 min, 50 °C for 5 min,
and 98 °C for 5 min. qPCR was performed using Fast
SYBR Green Master Mix, as per manufacturer in-
structions (Applied Biosystems Inc., Foster City, CA,
USA), and β-actin was used for normalization. The
amplification conditions were the following: 1 min at
95 °C, followed by 40 cycles of 15 s at 95 °C and
1 min at 60 °C.
The LDOC1 primers were (forward) 5′-CTA TGC
TGC CAC TTC ACA TCC-3′ and (reverse) 5′-GTG
AGC TGT CCA AAT CAA TGT C-3′. Each reaction was
performed in triplicate. We used the 2-Δ CT method to cal-
culate the relative expression levels of the target gene.
LDOC1 expression in thyroid tissues was log2-transformed
and expressed as the LDOC1/β-actin expression ratio
(−Δ CT).
Antibodies, western blot analysis, and
immunohistochemistry
Primary antibodies against the following proteins were
from commercial sources: p65 (F-6; sc-8008), IκBα
(6A920; sc-56710), tubulin (sc-5286), and Bcl-xL (sc-1041),
Santa Cruz Biotechnology (Dallas, TX, USA); β-actin
(D110024) and Bax (AB20073b), Sangon Biotech (Shanghai,
China); cleaved PARP (Asp214; #9541) and cleaved
caspase-3 (Asp175, 5A1E; #9664), Cell Signaling
Technology (Beverly, MA, USA); and LDOC1 (ab98390),
Abcam (Cambridge, UK). Goat anti-rabbit IgG-
horseradish peroxidase (HRP) (sc-2030) and goat anti-
mouse IgG-HRP (sc-2031) secondary antibodies were
from Santa Cruz Biotechnology.
Cytoplasmic and nuclear protein extracts were ob-
tained using a ProteoJET Cytoplasmic and Nuclear Pro-
tein Extraction Kit (Fermentas, Glen Burnie, MD, USA),
according to the manufacturer’s instructions. Total pro-
tein (30–50 mg) or proteins from the nuclear/cytoplas-
mic fraction (15 mg) were separated by means of SDS-
PAGE and then transferred onto PVDF membranes. The
membranes were incubated with primary antibodies
overnight at 4 °C, after which the target proteins were
visualized by incubating the blots with species-specific
HRP-conjugated secondary antibodies and then with
an enhanced chemiluminescence reagent (Amersham
Biosciences Corp., Piscataway, NJ, USA). Antibodies
against β-actin, tubulin, and histone H2A were used
as controls to normalize protein input. Western blot
bands were quantified using Image J analysis software.
We stained 5-μm-thick thyroid tissue sections by using
the ABC reagent kit (Vector Laboratories, Burlingame,
CA, USA) as specified by the supplier. LDOC1 expression
in normal and malignant samples was semi-quantitatively
scored according to methods presented by Pinheiro et al.
[31]. The final degree of immunoreactivity was deter-
mined by the sum of the staining intensity and the area of
positive staining; samples were grouped according to
negative (0), weak (1–2), moderate (3), or strong (4–6)
staining. The positive-staining category included only
samples that exhibited moderate and strong staining;
samples that received other final scores were regarded
as negative. For p65 expression, only nuclear immu-
noreactivity was regarded as constitutive NF-κB acti-
vation and specimens were considered positive if
10 % or more of tumor cells were nuclear stained as
previously described [32].
Cell cycle analysis
To monitor LDOC1-induced changes in the cell cycle,
2 × 105 cells were plated per well in 6-well plates over-
night and then serum-starved for synchronization in
G0/G1 phase. After synchronization for 24 h, fetal bo-
vine serum (FBS) was added to the cultures to promote
cell cycle reentry and the cells were concomitantly
treated with recombinant human TGF-β1 (rTGF-β1;
Peprotech, Rocky Hill, NJ, USA). Subsequently, the cells
were fixed at various times and stained with propidium
iodide (BB-4104-2; BestBio, Shanghai, China) according
to the manufacturer’s procedures, and then measured
using flow cytometry analysis performed on a Guava
EasyCyte Mini System (Guava Technologies, Billerica,
MA, USA).
Cell proliferation assay
Cell viability and cell numbers were assessed using Cell
Counting Kit-8 (CCK-8) (BB-4202-2; BestBio, Shanghai,
China); assays were performed in 96-well plates in tripli-
cate. Cells were seeded at 1000 cells/well in 200 μL of
culture medium the day before treatment. Cell numbers
were determined daily for 7 days after seeding, or the
cells were treated with a stimulator (TNFα or rTGF-β1)
at various times and then the 450-nm absorbance of
the samples was measured using a 96-well microplate
reader.
Apoptosis assay
TPC-1 cells (2 × 105 cells/well) infected with Lv-LDOC1
or Lv-NC were seeded in 6-well plates and serum-
starved for 1 day, and then the culture medium was
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replaced with culture medium containing 10 % FBS;
24 h after medium replacement, apoptosis was examined
using an APC-conjugated Annexin V and 7-AAD
apoptosis-detection kit (BD Biosciences, Franklin Lakes,
NJ, USA), according to manufacturer instructions.
NF-κB-luciferase reporter assay
Transduced TPC-1 cells were transiently transfected
with the NFκB-driven firefly-luciferase reporter vector
by using the FuGENE 6 transfection reagent (Roche
Diagnostics GmbH, Mannheim, Germany) according to
manufacturer instructions. At 24 h post-transfection, the
culture medium was replaced with serum-free medium,
and 24 h later, the cells were treated with or without
TNFα. The cells were then collected and analyzed for
firefly luciferase activities by using the ONE-Glo lucif-
erase assay system (Promega, Madison, WI, USA) ac-
cording to the product manual. Transfections were
performed in triplicate.
Statistical analysis
The results are presented as means ± SEM of three inde-
pendent experiments performed in at least triplicate.
The data were analyzed using SPSS 19.0 software (SPSS,
Chicago, IL, USA). A two-tailed Student’s t test was used
for comparisons between two groups, and ANOVA and
Newman-Keuls tests were used for multiple compari-
sons. Pearson chi-square test was performed to analyze
possible associations between LDOC1 and nuclear p65
content in tissue samples. Graphs were generated using
GraphPad Prism Software version 5.0 (San Diego, CA,
USA). P < 0.05 was considered statistically significant.
Results
LDOC1 expression is reduced and is associated with both
primary tumor size and nuclear p65 content in human
PTC
To define the expression profile of LDOC1 in hu-
man PTC tissues, qRT-PCR was performed on 126
PTC surgical specimens (Table 1) and 47 normal hu-
man thyroid tissues. LDOC1 expression was drastically
downregulated in PTC samples as compared with the
expression in normal thyroids (Fig. 1a), but LDOC1 ex-
pression did not differ markedly between classic PTCs
and other histological PTC variants (data not shown).
Table 1 Clinicopathological features of the study cohort
Characteristics Number
No. of patients 126
Age (mean ± SD), years 44.8 ± 12.7
Sex (male/female) 34/92
Histological variant (cPTC/other) 101/20
Tumor size (T1/T2/T3)a 81/28/17
Extrathyroidal extension (absent/present) 97/29
Distant metastasis 0
aTumor size: T1 < 2 cm; T2 > 2 cm, but ≦4 cm; T3 > 4 cm
Fig. 1 LDOC1 mRNA expression is downregulated in papillary
thyroid carcinoma (PTC) tissues. a LDOC1 mRNA expression
compared between PTC (n = 126) and normal (n = 47) tissue
samples. b Comparison of LDOC1 mRNA expression in normal
and PTC samples according to tumor T status. c Relative expression of
LDOC1 with or without the presence of extrathyroidal extension. All
quantitative reverse transcription-PCR (qRT-PCR) data are shown as
means ± SEM from triplicate assays after normalization against β-actin.
LDOC1 expression is log2-transformed and expressed as the
LDOC1/β-actin expression ratio (−Δ CT)
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Decreased LDOC1 mRNA expression correlated inversely
with increased primary tumor size in PTC (Fig. 1b); how-
ever, low LDOC1 expression was not associated with the
presence of extrathyroidal invasion (Fig. 1c).
Next, we analyzed LDOC1 and nuclear P65 expression
levels in paraffin-embedded samples by performing im-
munohistochemical staining (Tables 2, 3 and Fig. 2). As
expected based on the aforementioned results, LDOC1
expression was extremely low or absent in PTC samples
(Fig. 2a, b) and moderate or high in normal thyroids
(Fig. 2d). Notably, when LDOC1 was detectable in PTC
samples, the protein was mislocalized from the nucleus
to the cytoplasm (Fig. 2c). Nuclear P65 expression was
observed in a high percentage of PTC (42/56, 75.0 %),
whereas only 6 out of 33 cases (18.2 %) showed positive
nuclear staining in normal thyroid. The specificity of the
staining was validated by a lack of tissue immunoreactiv-
ity upon omission of the primary antibody (Fig. 2g, h).
As shown in Table 3, the results also revealed that there
is a correlation between LDOC1 and nuclear P65 ex-
pression in human PTC tissues.
Lentivirus-mediated LDOC1 stable expression in the PTC
cell line TPC-1
We evaluated LDOC1 mRNA expression in two human
PTC-derived cell lines (BCPAP and TPC-1) and there
was a significantly lower expression of LDOC1 with re-
spect to normal thyroid tissue (Fig. 3a). As a first step in
determining the biological relevance of reduced LDOC1
expression in PTC, we stably overexpressed LDOC1 in
TPC-1 cells, which is an authentic thyroid cancer cell
line, as demonstrated by Schweppe et al. [33]. The cul-
tured TPC-1 cells were transduced with either a lenti-
viral vector designed for LDOC1 stable overexpression
(Lv-LDOC1) or the empty lentiviral vector (negative
control, Lv-NC) (Fig. 3b), and then selection was
performed using puromycin in order to enrich lentivirus-
infected cells. The efficacy of lentivirus-mediated LDOC1
overexpression was validated by means of flow cytometry,
qRT-PCR, and immunoblotting (Fig. 3c, d).
Elevated LDOC1 expression suppresses proliferation and
promotes apoptosis in TPC-1 cells
To investigate the biological effects of LDOC1 in PTC
cells, we measured the growth rate of TPC-1 cells by
performing the CCK-8 assay after restoration of LDOC1
expression. Cells transduced with the LDOC1 cDNA-
harboring vector grew considerably more slowly than
did untransduced (UNT) cells and cells transduced with
the negative control vector (Lv-NC) (Fig. 4a); LDOC1
overexpression led to a significant reduction in TPC-1
cell number by Day 7 (P < 0.05). Next, we examined the
molecular mechanism underlying this altered cell growth
by investigating how LDOC1 expression affected the cell
cycle distribution of TPC-1 cells after synchronization
induced through serum deprivation. Flow cytometry
analysis revealed that LDOC1 overexpression corre-
sponded with a statistically significant shift within the
DNA profile to a subG1 position; the proportion shifted
from 11.8 % in the case of negative-control cells to
17.1 % for LDOC1-overexpressing cells (Fig. 4b).
We also analyzed whether LDOC1 plays a role in
regulating apoptosis in TPC-1 cells. We used an
Annexin V-APC/7-AAD kit for these assays, and our re-
sults revealed that the apoptotic index of Lv-LDOC1-
infected cells was markedly higher than that of negative-
control cells (Fig. 4c). Furthermore, we measured the
levels of apoptosis-related proteins (Fig. 4d, e), and the
results demonstrated that LDOC1-overexpressing TPC-
1 cells expressed higher levels of cleaved caspase-3,
cleaved PARP, and Bax as compared with UNT and Lv-
NC cells. By contrast, Bcl-xL and c-Myc expression
levels were markedly decreased (relative to control) after
LDOC1 overexpression. Collectively, these results sug-
gest that LDOC1 promotes apoptosis in TPC-1 cells.
LDOC1 inhibits NF-κB signaling in TPC-1 cells
Our aforementioned results imply that a loss of LDOC1
expression contributes to cell survival and protects
against apoptosis. In cancer cells, one of the main signal-
ing pathways related to survival, chemoresistance, and
radiation-resistance is the NF-κB pathway. Therefore, we
investigated whether LDOC1 is involved in regulating
the NF-κB signal transduction pathway in PTC cells. Be-
cause NF-κB signaling in several cell types is known to
Table 2 Immunohistochemical analysis of LDOC1 expression in human PTC
Group No. of patients Negative (0) Weakly stained (1–2) Moderately stained (3) Strongly stained (4–6)
Cancer 56 29 18 7 2
Normal 33 1 4 13 15
Table 3 Correlations between LDOC1 and nuclear P65
expression in tumor tissues
LDOC1 Nuclear P65 Total Positive
rate (%)Positive Negative
Positive 3 6 9 33.3
Negative 39 8 47 83.0
Total 42 14 56 75.0
χ2 = 7.458
P = 0.006
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be potently induced by TNFα, we tested how the
restoration of LDOC1 expression affects TNFα-induced
NF-κB activation in TPC-1 cells. Toward this end, we
performed western blotting to examine the expression of
p65, a subunit of the NF-κB transcription complex, in
nuclear extracts after LDOC1 expression was restored in
TPC-1 cells. LDOC1 restoration resulted in diminished
nuclear NF-κB expression but elevated cytoplasmic NF-
κB expression (Fig. 5a). Moreover, TNFα treatment en-
hanced NF-κB activation almost 2.5-fold over the basal
level in Lv-NC cells, whereas this activation was signifi-
cantly impaired in TPC-1 cells following lentivirus-
mediated LDOC1 overexpression (P < 0.01), as shown by
the results of an NF-κB-luciferase reporter assay (Fig. 5b).
Lastly, LDOC1 also inhibited the degradation of IκBα,
an NF-κB inhibitor (Fig. 5c). These results suggested that
both constitutive and TNFα-inducible activation of NF-
κB signaling were modulated by LDOC1 overexpression
in thyroid cancer TPC-1 cells.
TNFα functions as a “double agent” that can induce
both the NF-κB-dependent cell-survival pathway and the
caspase-dependent apoptotic pathway [34, 35]. There-
fore, we further analyzed how LDOC1 expression af-
fected TNFα-induced antiproliferative activity in TPC-1
Fig. 2 Immunohistochemical analysis of LDOC1 and P65 expression in PTC and normal samples. a, c Representative images of LDOC1 in classic
PTC (400×): two different specimens. b Representative images of LDOC1 in follicular variants of PTC (400×). d Representative images of LDOC1 in
normal thyroid (400×). e Thyroid papillary carcinoma (400x), showing nuclear P65 immunoreactivity. f Normal thyroid (400x), negative for nuclear
P65 expression. g, h Negative controls for PTC and normal tissues (200×): staining without anti-LDOC1 antibody
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cells. In line with our other LDOC1 results, TNFα-
induced loss of cell viability was higher in LDOC1-
overexpressing TPC-1 cells than in Lv-NC cells (Fig. 5d),
and the protein levels of c-Myc and Bcl-xL were also
decreased significantly in the LDOC1-expressing cells
(Fig. 5c). Taken together, these data suggest that
LDOC1-mediated NF-κB inhibition markedly sensitized
the TPC-1 thyroid cancer cells to apoptosis in response
to extracellular stimulation.
LDOC1 increases TPC-1 cell sensitivity to TGF-β1
inhibitory signaling
TGF-β1 potently inhibits the proliferation of normal
epithelial cells; however, in neoplastic thyrocytes, this
antiproliferative effect of TGF-β1 can be overridden by
the activation of the NF-κB survival pathway [36]. Be-
cause the NF-κB pathway mediates the effect of TGF-β1
on survival, we investigated whether LDOC1 enhances
the sensitivity of TPC-1 cells to TGF-β1 inhibitory sig-
naling by suppressing NF-κB activation. In TPC-1 cells
overexpressing LDOC1, the nuclear translocation of p65
in response to rTGF-β1 treatment was decreased as
compared with that in Lv-NC cells (Fig. 6a); furthermore,
the expression level of IκBα in LDOC1-overexpressing
was higher than that in control cells. Thus, we next deter-
mined whether LDOC1-mediated ablation of the NF-κB
survival signal was sufficient for affecting the cell cycle
distribution of TPC-1 cells under exogenous TGF-β1
stimulation. As per our expectation, the results of
flow cytometry analysis showed that the DNA profile
Fig. 3 LDOC1 overexpression in the PTC-derived cell line TPC-1 by means of lentivirus-mediated cDNA expression. a LDOC1 expression in PTC cell
lines (BCPAP and TPC-1) and normal thyroid tissue (n = 47). Some representative results of immunoblotting are shown. b Representative images
of TPC-1 cells transduced with either a lentiviral vector carrying the LDOC1 cDNA (Lv-LDOC1) or the empty lentiviral vector (Lv-NC; negative
control, GFP only). c Flow cytometry analysis of the efficiency of lentivirus-mediated cDNA transduction. d LDOC1 overexpression in TPC-1 cells
validated using qRT-PCR and western blotting. LDOC1 expression was normalized relative to the level of the loading control β-actin. **P < 0.01
and ***P < 0.001
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exhibited a statistically significant shift to a subG1
position in Lv-LDOC1 cells as compared with that in
Lv-NC (Fig. 6b).
Lastly, we performed CCK-8 assays and evaluated
whether LDOC1 overexpression influences the viability
of TPC-1 cells under TGF-β1 stimulation. As compared
with Lv-NC cells, Lv-LDOC1 cells exhibited drastically
lower cell viability after treatment for 12 h with rTGF-β1
(5 ng/mL) (Fig. 6c); this indicated that LDOC1 overex-
pression, which leads to the inhibition of NF-κB activa-
tion, might partially restore TGF-β1 signal transduction.
Furthermore, these results confirmed that the antipro-
liferative effect of TGF-β1 is mediated by the NF-κB
survival pathway (Fig. 6b, c). Collectively, the results
of our analyses suggest that LDOC1-mediated NF-κB
repression plays a crucial role in the restoration of
PTC cell responsiveness to TGF-β1 antiproliferative
signaling.
Discussion
The involvement of aberrant deregulation of oncogene
expression in human PTC has been well documented.
However, little is known about the role in PTC of tumor
suppressors implicated in cellular processes associated
with tumorigenesis or tumor progression. Furthermore,
certain PTCs have been reported to not exhibit al-
terations in commonly implicated oncogenes. There-
fore, genes and mechanisms that currently remain
unidentified might also play critical roles in thyroid
carcinogenesis.
LDOC1 was previously identified as a differentially
expressed gene in certain human cancers; for example,
the gene was differentially expressed in pancreatic and
gastric cancer cell lines [16]. In this study, we used
a large number of specimens to compare the expres-
sion of LDOC1 in PTC tissues and normal samples. Our
results demonstrated that LDOC1 mRNA expression was
Fig. 4 Influence of LDOC1 overexpression on TPC-1 cell growth and apoptosis. a TPC-1 cell numbers: UNT cells and cells transduced with
Lv-LDOC1 or Lv-NC; cell numbers at the indicated times were estimated using CCK-8 proliferation assays. Compared with UNT cells, TPC-1 cells
transduced with Lv-LDOC1 showed a significant reduction in cell number starting from Day 3. b LDOC1 restoration induces an increment of cells
in subG1 phase. TPC-1 cells transduced with Lv-NC or Lv-LDOC1 were seeded into 6-well plates and cultured overnight and then serum-starved
for 24 h; next, the culture medium was replaced with medium containing FBS, and after culturing for another 24 h, the cells were trypsinized and
cell cycle distribution was analyzed by performing propidium iodide staining and flow cytometry. c Apoptosis assessment in TPC-1 cells. Cells
transduced as in (b) were collected and stained using an Annexin V-APC/7-AAD apoptosis-detection kit. The upper and lower right quadrants
display the percentages of apoptotic cells. d Levels of Bax, Bcl-2, and Bcl-xL determined using qRT-PCR. e Western blot analyses of Bax, Bcl-2,
Bcl-xL, caspase-3, and PARP; β-actin was used as a loading control. *P < 0.05, **P < 0.01, and ***P < 0.001
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downregulated in PTC specimens. Furthermore, our func-
tional studies supported the hypothesis that LDOC1 ex-
pression is associated with antiproliferative and apoptotic
effects in thyroid cells.
Here, we also observed that the reduction in
LDOC1 mRNA levels was associated with an increase
in the size of primary PTC tumors, and that LDOC1
mRNA was almost undetectable in certain specimens
Fig. 5 LDOC1 inhibits NF-κB activation in TPC-1 cells. a Immunoblotting analysis of p65 expression in the nucleus and the cytoplasm. TPC-1 cells
transduced with Lv-LDOC1 or Lv-NC were stimulated with TNFα (10 ng/mL) for 30 min. Proteins from nuclear and cytoplasmic fractions were
extracted and immunoblotted; histone H2A and β-actin were used as loading controls. b Stable LDOC1 overexpression inhibited basic and
TNFα-stimulated NF-κB activation. Cells transduced as in (a) were transiently transfected with an NF-κB-luciferase expression vector. At 24 h after
transfection, cells were serum-starved for a further 24 h, after which they were stimulated with TNFα (10 ng/mL) for 24 h and used in luciferase
activity assays. Results are presented as luciferase activity values relative to the value in cells transfected with the control vector. c Western blot
analysis of IκBα, c-Myc, Bax, and Bcl-xL in Lv-NC and Lv-LDOC1 cells. Cells were treated with TNFα (10 ng/mL) for 30 min or 24 h (IκBα), and
tubulin was used for normalization. All data (a-c) are representative of three independent experiments. d Viability of Lv-LDOC1 and Lv-NC cells
was determined using a CCK-8 proliferation assay. Cells were stimulated with the indicated concentrations of TNFα once every 2 days together
with fresh medium for 5 days. The data shown represent three independent experiments performed in triplicate
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in which the tumor size was >4 cm. Notably, in cer-
tain PTC samples in which LDOC1 was detectable,
the protein was delocalized from the nucleus to the
cytoplasm; by contrast, LDOC1 localized predomin-
antly to the nucleus in normal tissues. The protein
sequence of LDOC1 suggests that LDOC1 might
interact with other transcription factors through its
leucine zipper domain or regulate cell signaling by
providing an SH3-binding surface for proteins that
function in signaling cascades. The nucleus-to-cytoplasm
shift in PTC might interfere with the regular function of
LDOC1 [18].
As expected, restoration of LDOC1 expression in a
PTC cell line characterized by very low levels of LDOC1
expression was associated with a proapoptotic effect and
a reduction in cell proliferation. Cell numbers were dras-
tically decreased in TPC-1 cells in which the LDOC1
cDNA was expressed by means of lentiviral infection,
and these cells also exhibited a shift of the DNA profile
to a subG1 position, as revealed by flow cytometric
analysis of cell cycle progression. Furthermore, Annexin
V-APC/7-AAD staining also confirmed an increase in
the level of apoptosis of LDOC1-overexpressing cells.
Together, the data reported herein are consistent with
the view that LDOC1 downregulation is involved in the
process of PTC tumorigenesis and/or progression. The
results of this study also suggest that the mechanism
by which LDOC1 affects cell growth and apoptosis in-
volves LDOC1 regulation of NF-κB survival signaling,
particularly in response to various extracellular stimuli
such as TNFα and TGF-β1. Thus, LDOC1 might
serve as a promising novel biomarker and therapeutic
target for the diagnosis and treatment of PTC and
other cancers.
NF-κB is a widely recognized transcription factor that
regulates the expression of numerous genes involved in
inflammation, immune response, aberrant cell growth,
and apoptosis [37]. High constitutive expression of NF-
κB is a primary feature of cancer cells but not normal
cells, and this indicates the crucial role of NF-κB in
regulating tumorigenesis [38–40]. In normal cells,
NF-κB localizes in the cytoplasm by binding to its in-
hibitor IκBα. After cells are exposed to various stim-
uli, the IκBα protein is phosphorylated, ubiquitinated,
and degraded, following which the released NF-κB
complexes translocate to the nucleus and regulate the
transcription of target genes [41]. TNFα is commonly
recognized as a potent inducer of NF-κB activation in
several cell types. NF-κB has been shown to associate
with C/EBP transcription factors through an interaction
between the NF-κB Rel homology domain and a leucine
zipper-like motif in C/EBP family members. The LDOC1
protein also possesses a basic region-leucine zipper and is
localized in the nucleus, and thus LDOC1 might also
directly interact with NF-κB, although the detailed
mechanism involved remains unclear. In this study,
we confirmed that (a) LDOC1 expression was down-
regulated and was correlated with nuclear P65
Fig. 6 LDOC1 restores the responsiveness of TPC-1 cells to TGF-β1 inhibitory signaling. a TPC-1 cells transduced with Lv-NC or Lv-LDOC1 were
treated with or without rTGF-β1 (5 ng/mL) for the indicated times. The levels of nuclear p65 and IκBα were determined by performing western
blot analysis, with histone H2A and β-actin being used as loading controls, respectively. b, c Cell cycle arrest and cell viability were assessed in
Lv-NC or Lv-LDOC1 cells treated as in (a). *P < 0.05, **P < 0.01, and ***P < 0.001 compared with Lv-NC cells (Student’s t test). All data are presented
as means ± SEM from three independent experiments
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content in PTC tissues; (b) LDOC1 overexpression
exerted antiproliferative and proapoptotic effects; and
(c) LDOC1 inhibited both basal and TNFα-induced
NF-κB activation. Collectively, these data support the
notion that a loss of LDOC1 expression might en-
hance both the constitutive and the inducible activa-
tion of NF-κB signaling, and, consequently, contribute
to the process of thyroid carcinogenesis.
The TGF-β1 pathway plays a key role in the control
of thyroid cell numbers by mediating cell growth and
apoptotic effects under normal physiological condi-
tions. However, TGF-β1 also acts as a tumor promoter
during epithelial-mesenchymal transdifferentiation and
in mesenchyme-derived tumors. Therefore, rTGF-β1
plays a dual role in the regulation of epithelial cells de-
pending on the type and the state of the cells, poten-
tially inducing either apoptosis or survival. Although
the mechanisms by which thyroid tumor cells bypass
TGF-β1-mediated inhibitory signaling are not fully
understood, the effect of TGF-β1 on thyrocyte survival
has been shown to be mediated by TGF-β1 activation
of NF-κB [36]. The data reported herein demonstrated
that the upregulation of LDOC1 expression in a PTC
cell line, TPC-1, resulted in reductions of NF-κB acti-
vation and cell viability in response to rTGF-β1 stimu-
lation; this indicates that the inhibition of LDOC1
expression might represent a critical step in PTC cells,
a step that would lead to an increase in NF-κB activity
and thereby impair TGF-β1 inhibitory signaling. Thus,
this study provides a potential connection between
TGF-β1 effects and NF-κB survival signaling in human
thyroid carcinogenesis. Our finding might have sub-
stantial practical clinical implications, because therapies
based on targeting NF-κB are currently of considerable
interest. Nevertheless, multiple parallel signal transduction
pathways might also contribute to the disruption of
TGF-β1 inhibitory signaling in TPC-1 cells; for ex-
ample, TGF-β1 signal transduction can also be medi-
ated by a non-Smad pathway [42].
Conclusions
In summary, this study highlights the functionality of
LDOC1 in thyroid carcinogenesis. We demonstrated
that LDOC1 is downregulated in PTC tumor tissues and
in thyroid cancer cell lines (BCPAP and TPC-1), and
that LDOC1 expresion is relevant to tumor size and nu-
clear P65 content in PTC tissues. Furthermore, we found
that LDOC1 expression sensitizes thyroid cancer cells to
apoptosis by suppressing both basal and TNFα-induced
activation of NF-κB signaling, and, consequently, in-
creases the responsiveness of these cells to TGF-β1 in-
hibitory signaling. Therefore, LDOC1 targeting might
yield substantial diagnostic and therapeutic benefits for
patients with PTC.
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